FATE Fate Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FATE

Price (delayed)

$5.44

Market cap

$619.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.92

Enterprise value

$584.82M

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture ...

Highlights
The debt has declined by 5% year-on-year
FATE's EPS is up by 21% year-on-year but it is down by 17% since the previous quarter
The net income has grown by 19% YoY but it has contracted by 18% from the previous quarter
FATE's revenue has dropped by 95% year-on-year and by 90% since the previous quarter
The gross profit has dropped by 95% year-on-year and by 90% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.fatetherapeutics.com
Peers: SRPT PTCT BDX RNA

Key stats

What are the main financial stats of FATE
Market
Shares outstanding
113.83M
Market cap
$619.25M
Enterprise value
$584.82M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.27
Price to sales (P/S)
84.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.28
Earnings
Revenue
$6.48M
EBIT
-$190.05M
EBITDA
-$171.14M
Free cash flow
-$139.78M
Per share
EPS
-$1.92
Free cash flow per share
-$1.38
Book value per share
$4.29
Revenue per share
$0.06
TBVPS
$5.64
Balance sheet
Total assets
$569.89M
Total liabilities
$143.78M
Debt
$102.07M
Equity
$426.12M
Working capital
$349.01M
Liquidity
Debt to equity
0.24
Current ratio
8.69
Quick ratio
8.81
Net debt/EBITDA
0.2
Margins
EBITDA margin
-2,641.8%
Gross margin
100%
Net margin
-2,933.8%
Operating margin
-3,287.9%
Efficiency
Return on assets
-34.5%
Return on equity
-46.5%
Return on invested capital
-35.4%
Return on capital employed
-36.2%
Return on sales
-2,933.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FATE stock price

How has the Fate Therapeutics stock price performed over time
Intraday
0.74%
1 week
27.4%
1 month
66.87%
1 year
27.4%
YTD
45.45%
QTD
65.85%

Financial performance

How have Fate Therapeutics's revenue and profit performed over time
Revenue
$6.48M
Gross profit
$6.48M
Operating income
-$212.99M
Net income
-$190.05M
Gross margin
100%
Net margin
-2,933.8%
FATE's revenue has dropped by 95% year-on-year and by 90% since the previous quarter
The gross profit has dropped by 95% year-on-year and by 90% since the previous quarter
The net income has grown by 19% YoY but it has contracted by 18% from the previous quarter
FATE's operating income is up by 19% year-on-year but it is down by 12% since the previous quarter

Growth

What is Fate Therapeutics's growth rate over time

Valuation

What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
1.27
P/S
84.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
90.28
FATE's EPS is up by 21% year-on-year but it is down by 17% since the previous quarter
FATE's price to book (P/B) is 78% lower than its 5-year quarterly average of 5.8 but 15% higher than its last 4 quarters average of 1.1
The company's equity rose by 16% QoQ but it fell by 11% YoY
The stock's price to sales (P/S) is 167% more than its last 4 quarters average of 31.6 but 14% less than its 5-year quarterly average of 97.8
FATE's revenue has dropped by 95% year-on-year and by 90% since the previous quarter

Efficiency

How efficient is Fate Therapeutics business performance
The ROIC has contracted by 26% from the previous quarter
The ROE has contracted by 22% from the previous quarter
Fate Therapeutics's return on assets has decreased by 21% QoQ and by 6% YoY

Dividends

What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FATE.

Financial health

How did Fate Therapeutics financials performed over time
FATE's total assets is up by 13% since the previous quarter but it is down by 10% year-on-year
The total liabilities has contracted by 6% YoY but it has grown by 4.3% from the previous quarter
The debt is 76% smaller than the equity
The company's equity rose by 16% QoQ but it fell by 11% YoY
The company's debt to equity fell by 14% QoQ but it rose by 4.3% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.